70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM

PurposeIn congestive heart failure (CHF), aldosteronism may induce a syndrome that features oxi/nitrosative stress, a proinflammatory phenotype, soft tissue and bone wasting. We hypothesized aldosterone/1% NaCl treatment (ALDOST) in rats enhances urinary and fecal Ca2+ and Mg2+ excretion and leads t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of investigative medicine 2005-01, Vol.53 (1), p.S265-S266
Hauptverfasser: Chhokar, V. S., Sun, Y., Bhattacharya, S. K., Ahokas, R. A., Myers, L. K., Xing, Z., Smith, R. A., Gerling, I. C., Weber, K. T.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S266
container_issue 1
container_start_page S265
container_title Journal of investigative medicine
container_volume 53
creator Chhokar, V. S.
Sun, Y.
Bhattacharya, S. K.
Ahokas, R. A.
Myers, L. K.
Xing, Z.
Smith, R. A.
Gerling, I. C.
Weber, K. T.
description PurposeIn congestive heart failure (CHF), aldosteronism may induce a syndrome that features oxi/nitrosative stress, a proinflammatory phenotype, soft tissue and bone wasting. We hypothesized aldosterone/1% NaCl treatment (ALDOST) in rats enhances urinary and fecal Ca2+ and Mg2+ excretion and leads to systemic effects, including secondary hyperparathyroidism (SHPT).MethodsAt 1, 2, 4 and 6 weeks of ALDOST we monitored Ca2+ and Mg2+ excretion; ionized [Ca2+]o and [Mg2+]o, parathyroid hormone (PTH) and α1-antiproteinase activity (α1-AP) in plasma; bone mineral density (BMD) and bone strength (BS); total intracellular Ca2+ and Mg2+ in peripheral blood mononuclear cells (PBMC) and ventricular tissue; lymphocyte H2O2 production; and NADPH oxidase activation in ventricular tissue. A separate group received spironolactone (Spi), an aldosterone receptor antagonist. Age-/gender-matched unoperated and untreated rats served as controls.ResultsALDOST induced a marked (p < .05) and persistent rise (3-5 fold) in both 24 hour urinary and fecal Ca2+ and Mg2+ excretion at weeks 1-6, together with progressive reductions (p < .05) in plasma [Ca2+]o and [Mg2+]o, and elevation (p < .05) in PTH. A fall (P < .05) in BMD and BS was seen at weeks 4 and 6. An early, sustained increase (p < .05) in PBMC Ca2+ and Mg2+ and increase (p < .05) in ventricular tissue Ca2+ was seen at weeks 4 and 6 Plasma α1-AP activity was reduced (p < .05) while lymphocyte H2O2 production was increased (p < .05) at all time points and gp91phox-positive inflammatory cells invaded the perivascular space of intramural coronary arteries of both ventricles at weeks 4 and 6. Spi co-treatment attenuated (p < .05) urinary and fecal Ca2+ and Mg2+ excretion, prevented the fall in [Ca2+]o and [Mg2+]o, rescued BMD and BS, and prevented Ca2+ loading of PBMC and cardiomyocytes.ConclusionsAldosteronism promotes urinary and fecal Ca2+ and Mg2+ excretion leading to a fall in plasma ionized [Ca2+]o and [Mg2+]o with SHPT and bone resorption. PTH-mediated Ca2+ loading of PBMC and cardiac tissue induces oxi/nitrosative stress and results in a proinflammatory phenotype. SHPT accounts for this Ca2+ paradox and contributes to the pathophysiology of CHF with aldosteronism. This work was supported, in part, by NIH Training Grant GR HL07641 (to V.S.C.).
doi_str_mv 10.2310/6650.2005.00006.69
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1786935526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4045623311</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1096-4ef30cd61d7807e3b46857a414561dffd31b1f6b38be76f3740f2b590db6101d3</originalsourceid><addsrcrecordid>eNqNkMFOwkAQhjdGExF9AU-beC7O7nZntyfT0GKbACWlJHLasLSbSESwhYNv71Z8AOcyf2a-fyb5CXlkMOKCwTOi9ApAjsAXjjC6IgOmQAeao7r2GjQLpNTRLbnruh0ARxnxAXlRQLP1Ii0XcRlX2bos8iRfzmg8T2iVpXQcT8f5akb7dVK80WJC42lSLKu0LOYevCc3bvPRNQ9_fUhWk7QaZ8G0eM29ObAMIgzCxgnY1shqpUE1woaopdqELJR-5lwtmGUOrdC2UeiECsFxKyOoLTJgtRiSp8vdY3v4OjfdyewO5_bTvzRMaYyElBw9xS_Utj10Xds4c2zf95v22zAwfVCmD8r0QZnfoIx3DklwMdn97j_8D_8_YE0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1786935526</pqid></control><display><type>article</type><title>70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM</title><source>SAGE Complete</source><creator>Chhokar, V. S. ; Sun, Y. ; Bhattacharya, S. K. ; Ahokas, R. A. ; Myers, L. K. ; Xing, Z. ; Smith, R. A. ; Gerling, I. C. ; Weber, K. T.</creator><creatorcontrib>Chhokar, V. S. ; Sun, Y. ; Bhattacharya, S. K. ; Ahokas, R. A. ; Myers, L. K. ; Xing, Z. ; Smith, R. A. ; Gerling, I. C. ; Weber, K. T.</creatorcontrib><description><![CDATA[PurposeIn congestive heart failure (CHF), aldosteronism may induce a syndrome that features oxi/nitrosative stress, a proinflammatory phenotype, soft tissue and bone wasting. We hypothesized aldosterone/1% NaCl treatment (ALDOST) in rats enhances urinary and fecal Ca2+ and Mg2+ excretion and leads to systemic effects, including secondary hyperparathyroidism (SHPT).MethodsAt 1, 2, 4 and 6 weeks of ALDOST we monitored Ca2+ and Mg2+ excretion; ionized [Ca2+]o and [Mg2+]o, parathyroid hormone (PTH) and α1-antiproteinase activity (α1-AP) in plasma; bone mineral density (BMD) and bone strength (BS); total intracellular Ca2+ and Mg2+ in peripheral blood mononuclear cells (PBMC) and ventricular tissue; lymphocyte H2O2 production; and NADPH oxidase activation in ventricular tissue. A separate group received spironolactone (Spi), an aldosterone receptor antagonist. Age-/gender-matched unoperated and untreated rats served as controls.ResultsALDOST induced a marked (p < .05) and persistent rise (3-5 fold) in both 24 hour urinary and fecal Ca2+ and Mg2+ excretion at weeks 1-6, together with progressive reductions (p < .05) in plasma [Ca2+]o and [Mg2+]o, and elevation (p < .05) in PTH. A fall (P < .05) in BMD and BS was seen at weeks 4 and 6. An early, sustained increase (p < .05) in PBMC Ca2+ and Mg2+ and increase (p < .05) in ventricular tissue Ca2+ was seen at weeks 4 and 6 Plasma α1-AP activity was reduced (p < .05) while lymphocyte H2O2 production was increased (p < .05) at all time points and gp91phox-positive inflammatory cells invaded the perivascular space of intramural coronary arteries of both ventricles at weeks 4 and 6. Spi co-treatment attenuated (p < .05) urinary and fecal Ca2+ and Mg2+ excretion, prevented the fall in [Ca2+]o and [Mg2+]o, rescued BMD and BS, and prevented Ca2+ loading of PBMC and cardiomyocytes.ConclusionsAldosteronism promotes urinary and fecal Ca2+ and Mg2+ excretion leading to a fall in plasma ionized [Ca2+]o and [Mg2+]o with SHPT and bone resorption. PTH-mediated Ca2+ loading of PBMC and cardiac tissue induces oxi/nitrosative stress and results in a proinflammatory phenotype. SHPT accounts for this Ca2+ paradox and contributes to the pathophysiology of CHF with aldosteronism. This work was supported, in part, by NIH Training Grant GR HL07641 (to V.S.C.).]]></description><identifier>ISSN: 1081-5589</identifier><identifier>EISSN: 1708-8267</identifier><identifier>DOI: 10.2310/6650.2005.00006.69</identifier><language>eng</language><publisher>London: Sage Publications Ltd</publisher><ispartof>Journal of investigative medicine, 2005-01, Vol.53 (1), p.S265-S266</ispartof><rights>2015 American Federation for Medical Research, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015 American Federation for Medical Research, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Chhokar, V. S.</creatorcontrib><creatorcontrib>Sun, Y.</creatorcontrib><creatorcontrib>Bhattacharya, S. K.</creatorcontrib><creatorcontrib>Ahokas, R. A.</creatorcontrib><creatorcontrib>Myers, L. K.</creatorcontrib><creatorcontrib>Xing, Z.</creatorcontrib><creatorcontrib>Smith, R. A.</creatorcontrib><creatorcontrib>Gerling, I. C.</creatorcontrib><creatorcontrib>Weber, K. T.</creatorcontrib><title>70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM</title><title>Journal of investigative medicine</title><description><![CDATA[PurposeIn congestive heart failure (CHF), aldosteronism may induce a syndrome that features oxi/nitrosative stress, a proinflammatory phenotype, soft tissue and bone wasting. We hypothesized aldosterone/1% NaCl treatment (ALDOST) in rats enhances urinary and fecal Ca2+ and Mg2+ excretion and leads to systemic effects, including secondary hyperparathyroidism (SHPT).MethodsAt 1, 2, 4 and 6 weeks of ALDOST we monitored Ca2+ and Mg2+ excretion; ionized [Ca2+]o and [Mg2+]o, parathyroid hormone (PTH) and α1-antiproteinase activity (α1-AP) in plasma; bone mineral density (BMD) and bone strength (BS); total intracellular Ca2+ and Mg2+ in peripheral blood mononuclear cells (PBMC) and ventricular tissue; lymphocyte H2O2 production; and NADPH oxidase activation in ventricular tissue. A separate group received spironolactone (Spi), an aldosterone receptor antagonist. Age-/gender-matched unoperated and untreated rats served as controls.ResultsALDOST induced a marked (p < .05) and persistent rise (3-5 fold) in both 24 hour urinary and fecal Ca2+ and Mg2+ excretion at weeks 1-6, together with progressive reductions (p < .05) in plasma [Ca2+]o and [Mg2+]o, and elevation (p < .05) in PTH. A fall (P < .05) in BMD and BS was seen at weeks 4 and 6. An early, sustained increase (p < .05) in PBMC Ca2+ and Mg2+ and increase (p < .05) in ventricular tissue Ca2+ was seen at weeks 4 and 6 Plasma α1-AP activity was reduced (p < .05) while lymphocyte H2O2 production was increased (p < .05) at all time points and gp91phox-positive inflammatory cells invaded the perivascular space of intramural coronary arteries of both ventricles at weeks 4 and 6. Spi co-treatment attenuated (p < .05) urinary and fecal Ca2+ and Mg2+ excretion, prevented the fall in [Ca2+]o and [Mg2+]o, rescued BMD and BS, and prevented Ca2+ loading of PBMC and cardiomyocytes.ConclusionsAldosteronism promotes urinary and fecal Ca2+ and Mg2+ excretion leading to a fall in plasma ionized [Ca2+]o and [Mg2+]o with SHPT and bone resorption. PTH-mediated Ca2+ loading of PBMC and cardiac tissue induces oxi/nitrosative stress and results in a proinflammatory phenotype. SHPT accounts for this Ca2+ paradox and contributes to the pathophysiology of CHF with aldosteronism. This work was supported, in part, by NIH Training Grant GR HL07641 (to V.S.C.).]]></description><issn>1081-5589</issn><issn>1708-8267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkMFOwkAQhjdGExF9AU-beC7O7nZntyfT0GKbACWlJHLasLSbSESwhYNv71Z8AOcyf2a-fyb5CXlkMOKCwTOi9ApAjsAXjjC6IgOmQAeao7r2GjQLpNTRLbnruh0ARxnxAXlRQLP1Ii0XcRlX2bos8iRfzmg8T2iVpXQcT8f5akb7dVK80WJC42lSLKu0LOYevCc3bvPRNQ9_fUhWk7QaZ8G0eM29ObAMIgzCxgnY1shqpUE1woaopdqELJR-5lwtmGUOrdC2UeiECsFxKyOoLTJgtRiSp8vdY3v4OjfdyewO5_bTvzRMaYyElBw9xS_Utj10Xds4c2zf95v22zAwfVCmD8r0QZnfoIx3DklwMdn97j_8D_8_YE0</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>Chhokar, V. S.</creator><creator>Sun, Y.</creator><creator>Bhattacharya, S. K.</creator><creator>Ahokas, R. A.</creator><creator>Myers, L. K.</creator><creator>Xing, Z.</creator><creator>Smith, R. A.</creator><creator>Gerling, I. C.</creator><creator>Weber, K. T.</creator><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AM</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGRYB</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K7.</scope><scope>K9.</scope><scope>M0O</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PRQQA</scope><scope>Q9U</scope></search><sort><creationdate>200501</creationdate><title>70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM</title><author>Chhokar, V. S. ; Sun, Y. ; Bhattacharya, S. K. ; Ahokas, R. A. ; Myers, L. K. ; Xing, Z. ; Smith, R. A. ; Gerling, I. C. ; Weber, K. T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1096-4ef30cd61d7807e3b46857a414561dffd31b1f6b38be76f3740f2b590db6101d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chhokar, V. S.</creatorcontrib><creatorcontrib>Sun, Y.</creatorcontrib><creatorcontrib>Bhattacharya, S. K.</creatorcontrib><creatorcontrib>Ahokas, R. A.</creatorcontrib><creatorcontrib>Myers, L. K.</creatorcontrib><creatorcontrib>Xing, Z.</creatorcontrib><creatorcontrib>Smith, R. A.</creatorcontrib><creatorcontrib>Gerling, I. C.</creatorcontrib><creatorcontrib>Weber, K. T.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Criminal Justice Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Criminology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Criminal Justice</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Social Sciences</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of investigative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chhokar, V. S.</au><au>Sun, Y.</au><au>Bhattacharya, S. K.</au><au>Ahokas, R. A.</au><au>Myers, L. K.</au><au>Xing, Z.</au><au>Smith, R. A.</au><au>Gerling, I. C.</au><au>Weber, K. T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM</atitle><jtitle>Journal of investigative medicine</jtitle><date>2005-01</date><risdate>2005</risdate><volume>53</volume><issue>1</issue><spage>S265</spage><epage>S266</epage><pages>S265-S266</pages><issn>1081-5589</issn><eissn>1708-8267</eissn><abstract><![CDATA[PurposeIn congestive heart failure (CHF), aldosteronism may induce a syndrome that features oxi/nitrosative stress, a proinflammatory phenotype, soft tissue and bone wasting. We hypothesized aldosterone/1% NaCl treatment (ALDOST) in rats enhances urinary and fecal Ca2+ and Mg2+ excretion and leads to systemic effects, including secondary hyperparathyroidism (SHPT).MethodsAt 1, 2, 4 and 6 weeks of ALDOST we monitored Ca2+ and Mg2+ excretion; ionized [Ca2+]o and [Mg2+]o, parathyroid hormone (PTH) and α1-antiproteinase activity (α1-AP) in plasma; bone mineral density (BMD) and bone strength (BS); total intracellular Ca2+ and Mg2+ in peripheral blood mononuclear cells (PBMC) and ventricular tissue; lymphocyte H2O2 production; and NADPH oxidase activation in ventricular tissue. A separate group received spironolactone (Spi), an aldosterone receptor antagonist. Age-/gender-matched unoperated and untreated rats served as controls.ResultsALDOST induced a marked (p < .05) and persistent rise (3-5 fold) in both 24 hour urinary and fecal Ca2+ and Mg2+ excretion at weeks 1-6, together with progressive reductions (p < .05) in plasma [Ca2+]o and [Mg2+]o, and elevation (p < .05) in PTH. A fall (P < .05) in BMD and BS was seen at weeks 4 and 6. An early, sustained increase (p < .05) in PBMC Ca2+ and Mg2+ and increase (p < .05) in ventricular tissue Ca2+ was seen at weeks 4 and 6 Plasma α1-AP activity was reduced (p < .05) while lymphocyte H2O2 production was increased (p < .05) at all time points and gp91phox-positive inflammatory cells invaded the perivascular space of intramural coronary arteries of both ventricles at weeks 4 and 6. Spi co-treatment attenuated (p < .05) urinary and fecal Ca2+ and Mg2+ excretion, prevented the fall in [Ca2+]o and [Mg2+]o, rescued BMD and BS, and prevented Ca2+ loading of PBMC and cardiomyocytes.ConclusionsAldosteronism promotes urinary and fecal Ca2+ and Mg2+ excretion leading to a fall in plasma ionized [Ca2+]o and [Mg2+]o with SHPT and bone resorption. PTH-mediated Ca2+ loading of PBMC and cardiac tissue induces oxi/nitrosative stress and results in a proinflammatory phenotype. SHPT accounts for this Ca2+ paradox and contributes to the pathophysiology of CHF with aldosteronism. This work was supported, in part, by NIH Training Grant GR HL07641 (to V.S.C.).]]></abstract><cop>London</cop><pub>Sage Publications Ltd</pub><doi>10.2310/6650.2005.00006.69</doi></addata></record>
fulltext fulltext
identifier ISSN: 1081-5589
ispartof Journal of investigative medicine, 2005-01, Vol.53 (1), p.S265-S266
issn 1081-5589
1708-8267
language eng
recordid cdi_proquest_journals_1786935526
source SAGE Complete
title 70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A51%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=70%20HYPERPARATHYROIDISM%20AND%20THE%20CALCIUM%20PARADOX%20OF%20ALDOSTERONISM&rft.jtitle=Journal%20of%20investigative%20medicine&rft.au=Chhokar,%20V.%20S.&rft.date=2005-01&rft.volume=53&rft.issue=1&rft.spage=S265&rft.epage=S266&rft.pages=S265-S266&rft.issn=1081-5589&rft.eissn=1708-8267&rft_id=info:doi/10.2310/6650.2005.00006.69&rft_dat=%3Cproquest_cross%3E4045623311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1786935526&rft_id=info:pmid/&rfr_iscdi=true